UCSD-founded Shape Therapeutics has collected series A cash from NEA and CureDuchenne Ventures to progress its RNA gene editing technology.
Shape Therapeutics, a US-based RNA gene editing technology spinout of University of California, San Diego (UCSD), procured $35.5m of series A funding led by venture capital firm New Enterprise Associates yesterday.
The round also included a commitment from CureDuchenne Ventures, the philanthropic venture arm of Duchenne muscular dystrophy-focused research charity CureDuchenne.
Founded in 2018, Shape Therapeutics is working on genome editing technologies that enable the development of gene therapies for human diseases by re-engineering pieces of human RNA,…
